Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014

Internal Medicine Journal

Volumn 44, Issue 12, 2014, Pages 1333-1349

  Blyth, C C ^a,b,c,d   Gilroy, N M ^e,f   Guy, S D ^g   Chambers, S T ^h,i   Cheong, E Y ^j   Gottlieb, T ^j   Mcguinness, S L ^k   Thursky, K A ^l,m  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e New South Wales Agency for Clinical Innovation   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g WESTERN HEALTH   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j Department of Microbiology and Infectious Diseases   (Australia)

^k ROYAL DARWIN HOSPITAL   (Australia)

^l PETER MACCALLUM CANCER CENTRE   (Australia)

^m PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

more..

Author keywords

Antifungal therapy; Aspergillosis; Emerging fungal infection; Invasive mould disease; Mucormycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MILTEFOSINE; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CONSENSUS; EVIDENCE BASED PRACTICE; EYE ASPERGILLOSIS; FUNGAL ENDOCARDITIS; FUNGAL EYE INFECTION; FUNGAL STRAIN; FUSARIOSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INVASIVE ASPERGILLOSIS; MOULD; MUCORMYCOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PSEUDALLESCHERIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT DURATION; URINARY TRACT ASPERGILLOSIS; URINARY TRACT INFECTION; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; COMPLICATION; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; MICROBIOLOGY; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PRE-EXPOSURE PROPHYLAXIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CONSENSUS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, FUNGAL; EVIDENCE-BASED MEDICINE; FUSARIOSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES AS TOPIC; PRE-EXPOSURE PROPHYLAXIS;

EID: 84914817699     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12598     Document Type: Review

References (147)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ etal. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
2. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G etal. Invasive aspergillosis in recipients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-650.
3. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y etal. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17: 1882-1889.
4. Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young JA etal. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 664-673.
5. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L etal. Clinically driven diagnostic antifungal approach in neutropenic recipients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-674.
6. Neofytos D, Lu K, Hatfield-Seung A, Blackford A, Marr KA, Treadway S etal. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult recipients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis 2013; 75: 144-149.
7. Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M etal. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50: 1588-1597.
8. Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD etal. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38: 496-520.
9. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW etal. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
10. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012; 56: 3032-3042.
11. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU etal. Clinical epidemiology of 960 recipients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65: 453-464.
12. Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 2011; 66(Suppl 1): i25-35.
13. Hol JA, Wolfs TF, Bierings MB, Lindemans CA, Versluys AB, de Wildt A etal. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 2013; 49(1): 95-101.
14. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
15. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E etal. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
16. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R etal. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54: e449-455.
17. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D etal. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic recipients. Br J Haematol 1997; 98: 711-718.
18. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D etal. Liposomal amphotericin B for empirical therapy in recipients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
19. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R etal. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-1233.
20. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A etal. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological recipients. J Antimicrob Chemother 2009; 64: 1274-1281.
21. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345.
22. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45: 406-407.
23. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 2013; 26: 493-500.
24. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-3041.
25. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE etal. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-2391.
26. Cesaro S, Giacchino M, Locatelli F, Spiller M, Buldini B, Castellini C etal. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological recipients. BMC Infect Dis 2007; 7: 28.
27. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J etal. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in recipients with hematologic malignancies. Cancer 2003; 98: 292-299.
28. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
29. Marr KA, Schlamm HT, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR etal. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases; London 2012.
30. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 43: 1449-1455.
31. Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008; 61(Suppl 1): i41-44.
32. Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis 2005; 41(Suppl 6): S387-388.
33. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L etal. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in recipients with neutropenia. J Clin Oncol 2001; 19: 253-259.
34. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R etal. Treatment of invasive aspergillosis with posaconazole in recipients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
35. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB etal. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in recipients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
36. Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kroger N etal. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised recipients. Mycoses 2011; 54(Suppl 1): 39-44.
37. Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy recipients? Cancer 2010; 116: 5290-5296.
38. Coleman JM, Hogg GG, Rosenfeld JV, Waters KD. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery-case report and review of the literature. Neurosurgery 1995; 36: 858-863.
39. Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. Aspergillus endocarditis: a review of the literature. Int J Infect Dis 2010; 14: e1040-1047.
40. Riddell JT, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52: 648-653.
41. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990; 12: 1147-1201 (erratum in Rev Infect Dis 1991; 13: 345).
42. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
43. Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med Mycol 2009; 47(Suppl 1): S387-393.
44. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA etal. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
45. Antinori S, Corbellino M, Meroni L, Resta F, Sollima S, Tonolini M etal. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect 2013; 66: 218-238.
46. Pound MW, Townsend ML, Dimondi V, Wilson D, Drew RH. Overview of treatment options for invasive fungal infections. Med Mycol 2011; 49: 561-580.
47. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122: 302-310.
48. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA etal. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
49. Prabhu R, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10(Suppl 1): 31-47.
50. Kwon-Chung K. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54(Suppl 1): S8-15.
51. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S23-34.
52. Skiada A, Rigopoulos D, Larios G, Petrikkos G, Katsambas A. Global epidemiology of cutaneous zygomycosis. Clin Dermatol 2012; 30: 628-632.
53. Greenberg R, Scott L, Vaughn H, Ribes J. Zygomycosis(mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517-525.
54. Lanternier F, Sun H, Ribaud P, Singh NDP, Kontoyiannis D, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54: 1629-1636.
55. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F etal. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-1401.
56. Marr K, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
57. Garcia-Vidal C, Upton A, Kirby K, Marr K. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
58. Xhaard A, Porcher R, Dannaoui E etal. Mucormycosis after allo-geneic hematopoietic stem cell transplantation: a French Multicenter Cohort Study (2003-2008). Clin Microbiol Infect 2012; 18: e396-40.
59. Marty E, Cosimi L, Baden L. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem cell transplants. N Engl J Med 2004; 350: 950-952.
60. Siwek G, Dodgson K, De Magalhaes-Silverman M, Bartelt L, Kilborn S, Hoth P etal. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-587.
61. Imhof A, Balajee A, Fredrick D, Englund J, Marr K. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-746.
62. Wingard J, Carter S, Walsh T, Kurtzberg J, Small T, Baden L etal. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-5118.
63. Donnelly J, De Pauw B. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10(Suppl 1): 107-117.
64. Skiada S, Lanternier F, Groll A, Pagano L, Zimmerli S, Herbrecht R etal. Diagnosis and treatment of mucormycosis in recipients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98: 492-504.
65. Walsh T, Hiemenz J. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
66. Walsh T, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M etal. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in recipients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
67. Chamilos G, Lewis R, Kontoyiannis D. Delaying amphotericin B-based frontline therapy significantly increases mortality among recipients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.
68. Dannaoui E, Meletiadis J, Mouton JW, Meis JF. Verwiej PE. Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
69. Sun QN, Forthergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
70. Sun Q, Najvar L, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconzaole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2312.
71. Dannaoui E, Meis J, Loebenberg D, Verweij P. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-3650.
72. Spellberg B, Ibrahim A, Roilides E, Lewis R, Lortholary O, Petrikkos G etal. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012; 54(Suppl 1): S73-78.
73. Ibrahim A, Bowman J, Avanessian V, Brown K, Spellberg B, Edwards J etal. Caspofungin inhibits Rhizopus oryzae 1, 3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-727.
74. Reed C, Bryant R, Ibrahim A, Edwards J, Filler S, Goldberg R etal. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-371.
75. Ibrahim A, Gebremariam T, Schwartz J, Edwards J Jr, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53: 772-775.
76. Rodriguez M, Serena C, Marine M, Pastor F, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008; 52: 3786-3788.
77. Greenberg R, Mullane K, van Burik J-A, Raad I, Abzug M, Anstead G etal. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133.
78. van Burik J, Hare R, Solomon H, Corrado M, Kontoyiannis D. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-65.
79. Roden M, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, Schaufele R etal. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-654.
80. Ibrahim A, Gebermariam T, Fu Y, Lin L, Husseiny M, French S etal. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-2657.
81. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen G etal. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-3125.
82. Spellberg B, Ibrahim A, Chin-Hong P, Kontoyiannis D, Morris M, Perfect J etal. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67: 715-722.
83. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL etal. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-4450.
84. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in recipients with hematologic malignancies at a cancer center. J Infect 1998-2009; 60: 331-337.
85. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C etal. Outcome predictors of 84 recipients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315-319.
86. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-4431.
87. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J etal. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore) 2013; 92: 305-316.
88. Hof H. Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother 2001; 45: 2987-2990.
89. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR etal. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-1864.
90. Nucci M. Emerging moulds: fusarium, scedosporium and zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-612.
91. De Carolis E, Posteraro B, Lass-Florl C, Vella A, Florio AR, Torelli R etal. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2012; 18: 475-484.
92. Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium infection originating from paronychia in a neutropenic recipient: a case report and review of the literature. Cutis 2010; 85: 191-194.
93. Colombo A, Maccari G, Congiu T, Basso P, Baj A, Toniolo A. Colonization of a central venous catheter by the hyaline fungus fusarium solani species complex: a case report and SEM imaging. Case Rep Med 2013; 2013: 618358.
94. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in recipients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
95. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl 1): 67-75.
96. Kapp M, Schargus M, Deuchert T, Springer J, Wendel F, Loeffler J etal. Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient. Transpl Infect Dis 2011; 13: 374-379.
97. Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F etal. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic recipients. Ann Hematol 2014; 93: 493-498.
98. Wu CH, Lu PL, Hsiao HH, Liu TC, Lin SF, Chang CS etal. Breakthrough Fusarium solani infection in a recipient with acute myeloid leukemia receiving posaconazole prophylaxis. Ann Hematol 2014; 93: 1079-1081.
99. Sugawara Y, Nakase K, Nakamura A, Ohishi K, Sugimoto Y, Fujieda A etal. Clinical utility of a panfungal polymerase chain reaction assay for invasive fungal diseases in recipients with haematologic disorders. Eur J Haematol 2013; 90: 331-339.
100. Gonzalez GM, Marquez J, Trevino-Rangel Rde J, Palma-Nicolas JP, Garza-Gonzalez E, Cecenas LA etal. Murine model of disseminated fusariosis: evaluation of the fungal burden by traditional CFU and quantitative PCR. Mycopathologia 2013; 176: 219-224.
101. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35: 909-920.
102. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S etal. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-1242.
103. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-958.
104. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-3626.
105. Pereira MF, Berezin EN, Carvalho RL, Scheffer DK, Mimica MJ. Mupirocin susceptibility in Staphylococcus aureus nasal and oropharyngeal isolates from Brazilian children. J Chemother 2013; 1973947813Y0000000151. [Epub ahead of print].
106. Merz B. Aerosolized pentamidine promising in Pneumocystis therapy, prophylaxis. JAMA 1988; 259: 3223-3224.
107. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J etal. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
108. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B etal. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a recipient with acute leukemia. J Clin Microbiol 2003; 41: 4898-4900.
109. Rodriguez-Villalobos H, Georgala A, Beguin H, Heymans C, Pye G, Crokaert F etal. Disseminated infection due to Cylindrocarpon (Fusarium) lichenicola in a neutropenic recipient with acute leukaemia: report of a case and review of the literature. Eur J Clin Microbiol Infect Dis 2003; 22: 62-65.
110. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl 1): 48-66.
111. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated fusarium infection in an immunocompromised recipient. Clin Infect Dis 2003; 37: 311-313.
112. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G etal. Posaconazole as salvage treatment for invasive fusariosis in recipients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
113. Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C etal. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83: 394-397.
114. Neuburger S, Massenkeil G, Seibold M, Lutz C, Tamm I, le Coutre P etal. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10: 290-293.
115. Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143: 222-227.
116. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43: 1580-1584.
117. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T etal. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-197.
118. Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I etal. Treatment of scedosporiosis with voriconazole: clinical experience with 107 recipients. Antimicrob Agents Chemother 2008; 52: 1743-1750.
119. Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS etal. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-370.
120. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521-526.
121. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K etal. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
122. Harun A, Perdomo H, Gilgado F, Chen SC, Cano J, Guarro J etal. Genotyping of Scedosporium species: a review of molecular approaches. Med Mycol 2009; 47: 406-414.
123. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007; 13: 1170-1177.
124. Guarro J, Kantarcioglu AS, Horre R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J etal. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006; 44: 295-327.
125. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-117.
126. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE etal. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-68.
127. Wiederhold NP, Lewis RE. Antifungal activity against Scedosporium species and novel assays to assess antifungal pharmacodynamics against filamentous fungi. Med Mycol 2009; 47: 422-432.
128. Trubiano JA, Paratz E, Wolf M, Teh BW, Todaro M, Thursky KA etal. Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Mycoses 2014.
129. Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SC. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother 2013; 68: 2842-2846.
130. Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect 2000; 6: 336-337.
131. Grenouillet F, Botterel F, Crouzet J, Larosa F, Hicheri Y, Forel JM etal. Scedosporium prolificans: an emerging pathogen in France? Med Mycol 2009; 47: 343-350.
132. Das S, Saha R, Dar SA, Ramachandran VG. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis. Mycopathologia 2010; 170: 361-375.
133. Alanio A, Brethon B, Feuilhade de Chauvin M, de Kerviler E, Leblanc T, Lacroix C etal. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic recipient successfully treated with voriconazole combined with caspofungin. Clin Infect Dis 2008; 46: e116-118.
134. Kantarcioglu AS, Celkan T, Yucel A, Mikami Y, Kurugoglu S, Mitani H etal. Fatal Trichoderma harzianum infection in a leukemic pediatric recipient. Med Mycol 2009; 47: 207-215.
135. Lagrange-Xelot M, Schlemmer F, Gallien S, Lacroix C, Molina JM. Trichoderma fungaemia in a neutropenic recipient with pulmonary cancer and human immunodeficiency virus infection. Clin Microbiol Infect 2008; 14: 1190-1192.
136. De Ravin SS, Challipalli M, Anderson V, Shea YR, Marciano B, Hilligoss D etal. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011; 52: e136-143.
137. Giraud S, Pihet M, Razafimandimby B, Carrere J, Degand N, Mely L etal. Geosmithia argillacea: an emerging pathogen in recipients with cystic fibrosis. J Clin Microbiol 2010; 48: 2381-2386.
138. Chowdhary A, Kathuria S, Singh PK, Agarwal K, Gaur SN, Roy P etal. Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses. Antimicrob Agents Chemother 2013; 57: 2845-2848.
139. Chen SC, Blyth CC, Sorrell TC, Slavin MA. Pneumonia and lung infections due to emerging and unusual fungal pathogens. Semin Respir Crit Care Med 2011; 32: 703-716.
140. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162-1176.
141. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH etal. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-1087.
142. Antas PR, Brito MM, Peixoto E, Ponte CG, Borba CM. Neglected and emerging fungal infections: review of hyalohyphomycosis by Paecilomyces lilacinus focusing in disease burden, in vitro antifungal susceptibility and management. Microbes Infect 2012; 14: 1-8.
143. Houbraken J, Verweij PE, Rijs AJ, Borman AM, Samson RA. Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol 2010; 48: 2754-2761.
144. Ioakimidou A, Vyzantiadis TA, Sakellari I, Arabatzis M, Smias C, Douka V etal. An unusual cluster of Acremonium kiliense fungaemias in a haematopoietic cell transplantation unit. Diagn Microbiol Infect Dis 2013; 75: 313-316.
145. Purnak T, Beyazit Y, Sahin GO, Shorbagi A, Akova M. A novel fungal pathogen under the spotlight - Acremonium spp. associated fungaemia in an immunocompetent host. Mycoses 2011; 54: 78-80.
146. Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC etal. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect 2014; 20(Suppl 3): 47-75.
147. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010; 23: 884-928.